On July 16, 2020, in connection with the IPO, Dr. Peter J. Fitzgerald, Dr. Linda Grais and Hon. Dr. David J. Shulkin (the “Directors”) were appointed to the board of directors of Deerfield Healthcare Technology Acquisitions Corp. The Directors are independent directors. Effective July 16, 2020, the Directors were appointed to the Board’s Audit Committee, with Dr. Grais serving as chair of the Audit Committee. Effective July 16, 2020, Drs. Fitzgerald, Grais and Shulkin were also appointed to the Board’s Compensation Committee, with Dr. Shulkin serving as chair of the Compensation Committee. Following the appointment of the Directors, the Board is comprised of the following three classes: the term of office of the first class of directors, Class I, consists of Drs. Grais and Shulkin and will expire at the Company’s first annual meeting of stockholders; the term of office of the second class of directors, Class II, consists of Richard Barasch and Steven Hochberg and will expire at the Company’s second annual meeting of stockholders; and the term of office of the third class of directors, Class III, consists of Dr. Fitzgerald and will expire at the Company’s third annual meeting of stockholders.